Company profile
SymphoRNA
One system. Multiple pathways. Any RNA.
- Industry
- Biotechnology Research
- Employees
- 12
- Founded
- 2025
SymphoRNA company summary
SymphoRNA is a company in the Biotechnology Research industry, founded in 2025. On LinkedIn the company has around 12 employees.
What technology does SymphoRNA use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About SymphoRNA
SymphoRNA is pioneering multi-target RNA medicines to treat the world’s most complex diseases. Most drugs focus on single targets, yet 70% of diseases involve multiple pathways. This is why so many treatments fail or deliver only limited benefit. Tackling complexity requires a new approach. In 2021, we developed a polysaccharide-based delivery system — safe, precise, and affordable, with proven in vivo performance. Unlike traditional lipid systems, it avoids PEG, is biodegradable, stable for 50+ days at room temperature, and capable of carrying multiple RNAs at once (mRNA, saRNA, siRNA). On this foundation, we built our therapeutic engine: programmable RNA “cocktails” that combine and tune multiple pathways at once, accelerated by AI-driven design. We are advancing our first programs in idiopathic pulmonary fibrosis while building a broader pipeline across fibrotic, inflammatory, and aging-related diseases. Our mission is clear: succeed where single-target approaches fail — and turn complexity into possibility for patients worldwide.
Compare companies similar to SymphoRNA
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
SymphoRNA symphorna.com | Biotechnology Research | 12 | 2025 | - |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about SymphoRNA
What does SymphoRNA do?
SymphoRNA is pioneering multi-target RNA medicines to treat the world’s most complex diseases. Most drugs focus on single targets, yet 70% of diseases involve multiple pathways. This is why so many treatments fail or deliver only limited benefit. Tackling complexity requires a new approach. In 2021, we developed a polysaccharide-based delivery system — safe, precise, and affordable, with proven in vivo performance. Unlike traditional lipid systems, it avoids PEG, is biodegradable, stable for 50+ days at room temperature, and capable of carrying multiple RNAs at once (mRNA, saRNA, siRNA). On this foundation, we built our therapeutic engine: programmable RNA “cocktails” that combine and tune multiple pathways at once, accelerated by AI-driven design. We are advancing our first programs in idiopathic pulmonary fibrosis while building a broader pipeline across fibrotic, inflammatory, and aging-related diseases. Our mission is clear: succeed where single-target approaches fail — and turn complexity into possibility for patients worldwide.
How many employees does SymphoRNA have?
SymphoRNA has around 12 employees on LinkedIn.
When was SymphoRNA founded?
SymphoRNA was founded in 2025.
Build a lead list from companies like SymphoRNA
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.